Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.

Thome J, Dittmann RW, Greenhill LL, Lipsius S, Tanaka Y, Bushe C, Escobar R, Heinloth AN, Upadhyaya H.

Atten Defic Hyperact Disord. 2017 Dec;9(4):219-229. doi: 10.1007/s12402-017-0227-8. Epub 2017 May 5.

PMID:
28477289
2.

Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA.

Brod M, Adler LA, Lipsius S, Tanaka Y, Heinloth AN, Upadhyaya H.

Atten Defic Hyperact Disord. 2015 Jun;7(2):141-50. doi: 10.1007/s12402-014-0160-z. Epub 2015 Jan 7.

3.

Validity of conners' adult attention-deficit/hyperactivity disorder rating Scale-investigator rated: screening version in patients from within and outside of Europe.

Sandra Kooij JJ, Keith Conners C, Goto T, Tanaka Y, Williams D, Allen AJ, Heinloth AN, Upadhyaya HP.

Psychiatry Res. 2013 Jun 30;208(1):94-6. doi: 10.1016/j.psychres.2012.12.003. Epub 2013 Jan 12.

PMID:
23318025
4.

Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain.

Skljarevski V, Frakes EP, Sagman D, Lipsius S, Heinloth AN, Dueñas Tentori HJ.

Pain Res Treat. 2012;2012:898347. doi: 10.1155/2012/898347. Epub 2012 Aug 29.

5.

Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder.

Houston JP, Zou W, Aris V, Fijal B, Chen P, Heinloth AN, Martinez J.

Psychiatry Res. 2012 Nov 30;200(1):63-5. doi: 10.1016/j.psychres.2012.06.002. Epub 2012 Jun 22.

PMID:
22727709
6.

Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis.

Houston JP, Lau K, Aris V, Liu W, Fijal BA, Heinloth AN, Perlis RH.

J Clin Psychiatry. 2012 Jun;73(6):878-85. doi: 10.4088/JCP.10m06744. Epub 2012 Mar 6.

PMID:
22480387
7.

Early improvement in pain predicts pain response at endpoint in patients with fibromyalgia.

Wang F, Ruberg SJ, Gaynor PJ, Heinloth AN, Arnold LM.

J Pain. 2011 Oct;12(10):1088-94. doi: 10.1016/j.jpain.2011.05.002. Epub 2011 Jul 18.

PMID:
21763211
8.

The association of single nucleotide polymorphisms in the catechol-O-methyltransferase gene and pain scores in female patients with major depressive disorder.

Fijal B, Perlis RH, Heinloth AN, Houston JP.

J Pain. 2010 Sep;11(9):910-5, 915.e1-9. doi: 10.1016/j.jpain.2009.12.016.

PMID:
20627703
9.

Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients.

Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP.

Biol Psychiatry. 2010 Jun 1;67(11):1110-3. doi: 10.1016/j.biopsych.2009.12.010. Epub 2010 Jan 27.

PMID:
20110084
10.

Therapeutic options for treatment-resistant depression.

Shelton RC, Osuntokun O, Heinloth AN, Corya SA.

CNS Drugs. 2010 Feb;24(2):131-61. doi: 10.2165/11530280-000000000-00000. Review.

PMID:
20088620
11.

Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients.

Houston JP, Fijal B, Heinloth AN, Adams DH.

Psychiatry Res. 2010 Jan 30;175(1-2):171-2. doi: 10.1016/j.psychres.2009.06.014. Epub 2009 Nov 5.

PMID:
19896213
12.

Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

Stauffer VL, Lipkovich I, Hoffmann VP, Heinloth AN, McGregor HS, Kinon BJ.

BMC Psychiatry. 2009 Mar 28;9:12. doi: 10.1186/1471-244X-9-12.

13.

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder.

Deberdt W, Lipkovich I, Heinloth AN, Liu L, Kollack-Walker S, Edwards SE, Hoffmann VP, Hardy TA.

Ther Clin Risk Manag. 2008 Aug;4(4):713-20.

14.

Gene set enrichment analysis for non-monotone association and multiple experimental categories.

Lin R, Dai S, Irwin RD, Heinloth AN, Boorman GA, Li L.

BMC Bioinformatics. 2008 Nov 14;9:481. doi: 10.1186/1471-2105-9-481.

15.

Answers to the most common questions about the hepatic safety profile of duloxetine.

Wohlreich MM, Acharya N, Strombom I, Kuritzky L, Robinson M, Heinloth AN, Regev A, Wernicke JF.

Postgrad Med. 2008 Jul;120(2):111-8. doi: 10.3810/pgm.2008.07.1803. Review.

PMID:
18654076
16.

Gene expression response in target organ and whole blood varies as a function of target organ injury phenotype.

Lobenhofer EK, Auman JT, Blackshear PE, Boorman GA, Bushel PR, Cunningham ML, Fostel JM, Gerrish K, Heinloth AN, Irwin RD, Malarkey DE, Merrick BA, Sieber SO, Tucker CJ, Ward SM, Wilson RE, Hurban P, Tennant RW, Paules RS.

Genome Biol. 2008;9(6):R100. doi: 10.1186/gb-2008-9-6-r100. Epub 2008 Jun 20.

17.

Genes related to apoptosis predict necrosis of the liver as a phenotype observed in rats exposed to a compendium of hepatotoxicants.

Huang L, Heinloth AN, Zeng ZB, Paules RS, Bushel PR.

BMC Genomics. 2008 Jun 16;9:288. doi: 10.1186/1471-2164-9-288.

18.

Blood gene expression signatures predict exposure levels.

Bushel PR, Heinloth AN, Li J, Huang L, Chou JW, Boorman GA, Malarkey DE, Houle CD, Ward SM, Wilson RE, Fannin RD, Russo MW, Watkins PB, Tennant RW, Paules RS.

Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18211-6. Epub 2007 Nov 2.

19.

Gene expression analysis offers unique advantages to histopathology in liver biopsy evaluations.

Heinloth AN, Boorman GA, Foley JF, Flagler ND, Paules RS.

Toxicol Pathol. 2007 Feb;35(2):276-83. Erratum in: Toxicol Pathol. 2007;35(6):850.

PMID:
17366322
20.
21.

Cdc7-Dbf4 and the human S checkpoint response to UVC.

Heffernan TP, Unsal-Kaçmaz K, Heinloth AN, Simpson DA, Paules RS, Sancar A, Cordeiro-Stone M, Kaufmann WK.

J Biol Chem. 2007 Mar 30;282(13):9458-68. Epub 2007 Feb 2.

22.

Application of visualization tools to the analysis of histopathological data enhances biological insight and interpretation.

Lobenhofer EK, Boorman GA, Phillips KL, Heinloth AN, Malarkey DE, Blackshear PE, Houle C, Hurban P.

Toxicol Pathol. 2006;34(7):921-8.

PMID:
17178692
23.

Optimal sampling of rat liver tissue for toxicogenomic studies.

Foley JF, Collins JB, Umbach DM, Grissom S, Boorman GA, Heinloth AN.

Toxicol Pathol. 2006;34(6):795-801.

24.

Phenotypic anchoring of acetaminophen-induced oxidative stress with gene expression profiles in rat liver.

Powell CL, Kosyk O, Ross PK, Schoonhoven R, Boysen G, Swenberg JA, Heinloth AN, Boorman GA, Cunningham ML, Paules RS, Rusyn I.

Toxicol Sci. 2006 Sep;93(1):213-22. Epub 2006 Jun 2.

25.

ATM requirement in gene expression responses to ionizing radiation in human lymphoblasts and fibroblasts.

Innes CL, Heinloth AN, Flores KG, Sieber SO, Deming PB, Bushel PR, Kaufmann WK, Paules RS.

Mol Cancer Res. 2006 Mar;4(3):197-207.

26.

Cellular and molecular targets of protein S-glutathiolation.

Shackelford RE, Heinloth AN, Heard SC, Paules RS.

Antioxid Redox Signal. 2005 Jul-Aug;7(7-8):940-50. Review.

PMID:
15998249
27.

Application of toxicogenomics to toxicology: basic concepts in the analysis of microarray data.

Irwin RD, Boorman GA, Cunningham ML, Heinloth AN, Malarkey DE, Paules RS.

Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:72-83. Review.

PMID:
15209406
28.

Gene expression profiling of rat livers reveals indicators of potential adverse effects.

Heinloth AN, Irwin RD, Boorman GA, Nettesheim P, Fannin RD, Sieber SO, Snell ML, Tucker CJ, Li L, Travlos GS, Vansant G, Blackshear PE, Tennant RW, Cunningham ML, Paules RS.

Toxicol Sci. 2004 Jul;80(1):193-202. Epub 2004 Apr 14.

PMID:
15084756
29.

ATM-dependent and -independent gene expression changes in response to oxidative stress, gamma irradiation, and UV irradiation.

Heinloth AN, Shackelford RE, Innes CL, Bennett L, Li L, Amin RP, Sieber SO, Flores KG, Bushel PR, Paules RS.

Radiat Res. 2003 Sep;160(3):273-90.

PMID:
12926986
30.

Identification of distinct and common gene expression changes after oxidative stress and gamma and ultraviolet radiation.

Heinloth AN, Shackelford RE, Innes CL, Bennett L, Li L, Amin RP, Sieber SO, Flores KG, Bushel PR, Paules RS.

Mol Carcinog. 2003 Jun;37(2):65-82.

PMID:
12766906
31.

An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage.

Heffernan TP, Simpson DA, Frank AR, Heinloth AN, Paules RS, Cordeiro-Stone M, Kaufmann WK.

Mol Cell Biol. 2002 Dec;22(24):8552-61.

32.

The Ataxia telangiectasia gene product is required for oxidative stress-induced G1 and G2 checkpoint function in human fibroblasts.

Shackelford RE, Innes CL, Sieber SO, Heinloth AN, Leadon SA, Paules RS.

J Biol Chem. 2001 Jun 15;276(24):21951-9. Epub 2001 Apr 4.

Supplemental Content

Loading ...
Support Center